SCHEMBL2305992

SCHEMBL2305992

COc1ccc2c(C)nnc(Cl)c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
DYRK1A Q13627 4/20 0.41
KDM4E B2RXH2 6/20 0.40
ALDH1A1 P00352 5/20 0.40
HPGD P15428 3/20 0.40
HSD17B10 Q99714 3/20 0.40
LMNA P02545 1/20 0.40
POLB P06746 1/20 0.40
MEN1 O00255 1/20 0.40
MAPT P10636 1/20 0.40
TSHR P16473 1/20 0.40
GFER P55789 1/20 0.40
KMT2A Q03164 1/20 0.40
GAA P10253 1/20 0.40
MAOA P21397 2/20 0.39
ACHE P22303 2/20 0.39
DYRK3 O43781 1/20 0.39
CCNT1 O60563 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30014669 1.00 SMN1; SMN2 (0.46) SMN1; SMN2NPC1RAB9ADYRK1AKDM4E
SCHEMBL2306186 0.93 SMN1; SMN2 (0.42) SMN1; SMN2NPC1RAB9ADYRK1AKDM4E
SCHEMBL26690613 0.89 KDM4E (0.45) SMN1; SMN2NPC1RAB9ADYRK1AKDM4E
SCHEMBL14543177 0.87 SMN1; SMN2 (0.53) SMN1; SMN2NPC1RAB9ADYRK1AKDM4E
SCHEMBL4724370 0.79 SMN1; SMN2 (0.46) SMN1; SMN2NPC1RAB9ADYRK1AKDM4E
SCHEMBL4122604 0.78 PDE4A (0.47) SMN1; SMN2DYRK1AKDM4EALDH1A1LMNA
SCHEMBL4124808 0.78 PDE4A (0.45) DYRK1AKDM4EALDH1A1HPGDHSD17B10
SCHEMBL4834669 0.78 HTT (0.48) SMN1; SMN2NPC1RAB9AKDM4EALDH1A1
SCHEMBL23562822 0.77 LMNA (0.40) SMN1; SMN2NPC1RAB9AKDM4EALDH1A1
SCHEMBL4125268 0.77 PDE5A (0.40) SMN1; SMN2ALDH1A1HPGDLMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270220-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. (US) 2025-08-28 US disclosed
US-12304915-B2 SOS1 inhibitors Mirati Therapeutics, Inc. (US) 2025-05-20 US disclosed
CN-119462626-A SOS1 inhibitors 米拉蒂治疗股份有限公司 2025-02-18 CN disclosed
CN-115135315-B SOS1 inhibitors 米拉蒂治疗股份有限公司 2024-11-26 CN disclosed
US-11702418-B2 SOS1 inhibitors Mirati Therapeutics, Inc. (US) 2023-07-18 US disclosed
US-11702418-B2 SOS1 inhibitors Mirati Therapeutics, Inc. (US) 2023-07-18 US disclosed
US-11702418-B2 SOS1 inhibitors Mirati Therapeutics, Inc. (US) 2023-07-18 US disclosed
US-20230137886-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. 2023-05-04 US disclosed
US-20230137886-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. 2023-05-04 US disclosed
US-20230137886-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. 2023-05-04 US disclosed
US-20090124624-A1 SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2009-05-14 US disclosed
US-20090124624-A1 SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2009-05-14 US disclosed
US-7423030-B2 1-amino-phthalazine derivatives, the preparation and the therapeutic use thereof SANOFI-AVENTIS (FR) 2008-09-09 US disclosed
EP-1940823-A2 SUBSTITUTED 1-AMINO-PHTHALZINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2008-07-09 EP disclosed
EP-1737840-B1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2007-09-12 EP disclosed
US-20070099895-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2007-05-03 US disclosed
WO-2007042660-A2 SUBSTITUTED 1-AMINO-PHTHALZINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2007-04-19 WO disclosed
WO-2007042660-A2 SUBSTITUTED 1-AMINO-PHTHALZINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2007-04-19 WO disclosed
EP-1737840-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2007-01-03 EP disclosed
WO-2005103033-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2005-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12304915-B2 SOS1 inhibitors SOS1, SOS2, SAV1 SMN1; SMN2 1579/4885NPC1 759/4885RAB9A 1260/4885
US-20230137886-A1 SOS1 INHIBITORS SOS1, SOS2, SAV1 SMN1; SMN2 1579/4885NPC1 759/4885RAB9A 1260/4885
US-20070099895-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF CYP11B2, CYP11B1, GOT2 SMN1; SMN2 1239/4885NPC1 204/4885RAB9A 3275/4885
US-20250270220-A1 SOS1 INHIBITORS SOS1, SOS2, SAV1 SMN1; SMN2 1579/4885NPC1 759/4885RAB9A 1260/4885
US-20090124624-A1 SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AGTR1, AGTR2, AHR SMN1; SMN2 2592/4885NPC1 1164/4885RAB9A 2174/4885
US-11702418-B2 SOS1 inhibitors SOS1, SOS2, SOST SMN1; SMN2 1762/4885NPC1 517/4885RAB9A 951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.